Remdesivir
Remdesivir is a topic covered in the Johns Hopkins HIV Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Remdesivir is approved for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization in adult and pediatric patients (12 years of age and older, and who weigh at least 40kg)
- Remdesivir is not FDA approved in children < 12 years of age, but remains authorized for use in the U.S. by the FDA under an Emergency Use Authorization (EUA) for treatment of suspected or laboratory-confirmed SARS-Co-2 infection (COVID-19) in children hospitalized with severe diseases.
- Severe disease is defined as:
- Patients with SpO2 ≤ 94% on room air, OR
- Requiring supplemental oxygen, OR
- Requiring mechanical ventilation, OR
- Requiring extracorporeal membrane oxygenation (ECMO)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Remdesivir is approved for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization in adult and pediatric patients (12 years of age and older, and who weigh at least 40kg)
- Remdesivir is not FDA approved in children < 12 years of age, but remains authorized for use in the U.S. by the FDA under an Emergency Use Authorization (EUA) for treatment of suspected or laboratory-confirmed SARS-Co-2 infection (COVID-19) in children hospitalized with severe diseases.
- Severe disease is defined as:
- Patients with SpO2 ≤ 94% on room air, OR
- Requiring supplemental oxygen, OR
- Requiring mechanical ventilation, OR
- Requiring extracorporeal membrane oxygenation (ECMO)
There's more to see -- the rest of this entry is available only to subscribers.